Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Interleukin-2: Started two Phase III trials with partner Eli Lilly, enrolling 120 and 64 patients, respectively. Each trial will test two doses, 9 and 18 µg/kg

Seragen Inc. (SRGN), Hopkinton, Mass.
Product:

Read the full 60 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE